Altimmune Announces Second Quarter 2026 Financial Results and Business Update
Altimmune reported positive topline results from the RECLAIM Phase 2 trial of pemvidutide in alcohol use disorder (AUD), where the drug met the primary endpoint of reducing heavy drinking days. The company initiated the global PERFORMA Phase 3 trial in MASH and completed enrollment in the RESTORE Phase 2 trial in ALD, backed by a strong cash position of $519 million.
Key figures
- Revenue
- 0
- Guidance
- PERFORMA Phase 3 MASH trial 52-week data readout anticipated in 2029; RESTORE Phase 2 ALD trial topline data expected in second half of 2027
- Net loss
- $22.8 million
- Ga expenses
- $7.6 million
- Rd expenses
- $18.7 million
- Cash position
- $519 million
- Interest income
- $4.5 million
- Offering proceeds
- $225.0 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.